<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37951998</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>19688</StartPage><MedlinePgn>19688</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">19688</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-46912-4</ELocationID><Abstract><AbstractText>We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who took nirmatrelvir/ritonavir and 250 who did not. The primary outcome was the development of one or more of eleven prespecified long COVID symptoms, assessed through a structured telephone interview four months after the positive SARS-CoV-2 test. Multivariable logistic regression models controlled for age, sex, race/ethnicity, chronic conditions, and COVID-19 vaccination status. We found that participants who took nirmatrelvir/ritonavir were no less likely to develop long COVID symptoms, compared to those who did not take the medication (44% vs. 49.6%, p&#x2009;=&#x2009;0.21). Taking nirmatrelvir/ritonavir was associated with a lower odds of two of the eleven long COVID symptoms, brain fog (OR 0.58, 95% CI 0.38-0.88) and chest pain/tightness (OR 0.51, 95% CI 0.28-0.91). Our finding that treatment with nirmatrelvir/ritonavir was not associated with a lower risk of developing long COVID is different from prior studies that obtained data only from electronic medical records.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Congdon</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. scongdon@montefiore.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narrowe</LastName><ForeName>Zev</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yone</LastName><ForeName>Nang</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunn</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nori</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowman</LastName><ForeName>Kelsie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rikin</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starrels</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7R9A5P7H32</RegistryNumber><NameOfSubstance UI="C000718217">nirmatrelvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002637" MajorTopicYN="N">Chest Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>11</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37951998</ArticleId><ArticleId IdType="pmc">PMC10640584</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-46912-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-46912-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open. 2021 doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Sivan M, Delaney B, Evans R, Milne R. Long covid-an update for primary care. BMJ. 2022;378:e072117. doi: 10.1136/bmj-2022-072117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072117</ArticleId><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services, Office of the Assistant Secretary for Health. National Research Action Plan on Long COVID. Available at: https://www.covid.gov/assets/files/National-Research-Action-Plan-on-Long-COVID-08012022.pdf/. Accessed December 20, 2022 Dec 20.</Citation></Reference><Reference><Citation>Vanichkachorn G, et al. Post-COVID-19 syndrome (long haul syndrome): Description of a multidisciplinary clinic at mayo clinic and characteristics of the initial patient cohort. Mayo Clin. Proc. 2021;96:1782&#x2013;1791. doi: 10.1016/j.mayocp.2021.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.04.024</ArticleId><ArticleId IdType="pmc">PMC8112396</ArticleId><ArticleId IdType="pubmed">34218857</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat. Commun. 2022;13:1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir. Med. 2022;10:761&#x2013;775. doi: 10.1016/S2213-2600(22)00127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study. Lancet Respir Med. 2022;10:863&#x2013;876. doi: 10.1016/S2213-2600(22)00126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Census Bureau. Long COVID Household Pulse Survey, 2022&#x2013;2023. Available at: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm/. Accessed July 20, 2023.</Citation></Reference><Reference><Citation>Bach, K. New Data shows long Covid is keeping as many as 4 million people out of work. Available at: https://www.brookings.edu/research/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/. Accessed December 28, 2022.</Citation></Reference><Reference><Citation>Tsampasian V, et al. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Inter. Med. 2023;183:566&#x2013;580. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat. Commun. 2021;12:6571. doi: 10.1038/s41467-021-26513-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Nasal and plasma severe acute respiratory syndrome coronavirus 2 RNA levels are associated with timing of symptom resolution in the ACTIV-2 trial of nonhospitalized adults with coronavirus disease 2019. Clin Infect Dis. 2023;76:734&#x2013;737. doi: 10.1093/cid/ciac818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac818</ArticleId><ArticleId IdType="pmc">PMC9619579</ArticleId><ArticleId IdType="pubmed">36210483</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, et al. Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 2023;183:554&#x2013;564. doi: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg DJ, et al. COVID-19 mortality by race and ethnicity in US metropolitan and nonmetropolitan areas, March 2020 to February 2022. JAMA Netw. Open. 2023;6:e2311098. doi: 10.1001/jamanetworkopen.2023.11098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.11098</ArticleId><ArticleId IdType="pmc">PMC10155069</ArticleId><ArticleId IdType="pubmed">37129894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mude W, Oguoma VM, Nyanhanda T, Mwanri L, Njue C. Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis. J. Glob. Health. 2021;11:05015. doi: 10.7189/jogh.11.05015.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.11.05015</ArticleId><ArticleId IdType="pmc">PMC8248751</ArticleId><ArticleId IdType="pubmed">34221360</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Census Bureau. QuickFacts, Bronx County, New York. Available at: https://www.census.gov/quickfacts/fact/table/bronxcountynewyork/PST045221. Accessed December 28, 2022.</Citation></Reference><Reference><Citation>Food and Drug Administration. Fact Sheet For Healthcare Providers: Emergency Use Authorization for PaxlovidTM. Available at: https://www.fda.gov/media/155050/download. Accessed December 28, 2022.</Citation></Reference><Reference><Citation>Centers For Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed December 28, 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009770</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Health. Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/. Accessed December 28, 2022.</Citation></Reference><Reference><Citation>Perlis RH, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw. Open. 2022 doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, et al. Development and validation of the long coronavirus disease (COVID) symptom and impact tools: A set of patient-reported instruments constructed from patients' lived experience. Clin. Infect. Dis. 2022;74:278&#x2013;287. doi: 10.1093/cid/ciab352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat. Commun. 2022;13:5663. doi: 10.1038/s41467-022-33415-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, et al. Use of cardiopulmonary exercise testing to evaluate long COVID-19 symptoms in adults: A systematic review and meta-analysis. JAMA Netw. Open. 2022 doi: 10.1001/jamanetworkopen.2022.36057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.36057</ArticleId><ArticleId IdType="pmc">PMC9557896</ArticleId><ArticleId IdType="pubmed">36223120</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs. Delta variants. Nat. Commun. 2022;13:7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934&#x2013;1946. doi: 10.1001/jama.2023.8823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol E. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer TK, et al. Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January&#x2013;July 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:1359&#x2013;1365. doi: 10.15585/mmwr.mm7143a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7143a2</ArticleId><ArticleId IdType="pmc">PMC9620572</ArticleId><ArticleId IdType="pubmed">36301738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndugga, N., Hill, L. &amp; Artiga, S. COVID-19 Cases and Deaths, Vaccinations and Treatments by Race/Ethnicity as of Fall 2022. Available at: https://www.kff.org/racial-equity-and-health-policy/issue-brief/covid-19-cases-and-deaths-vaccinations-and-treatments-by-race-ethnicity-as-of-fall-2022/. Accessed December 28, 2022.</Citation></Reference><Reference><Citation>Notarte KI, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard SA, et al. Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw. Open. 2022;6:e2251360. doi: 10.1001/jamanetworkopen.2022.51360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.51360</ArticleId><ArticleId IdType="pmc">PMC9857077</ArticleId><ArticleId IdType="pubmed">36652247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>